Today, Chen Li, the CEO of Hualing Pharmaceutical, announced at the Ninth Pharmaceutical Innovation and Investment Conference the completion of two clinical studies: first, the successful completion of the SENSITIZE 2 study in collaboration with Professor Juliana Chan's team from the Chinese University of Hong Kong. The results show that "using hyperglycemic clamp technology, a single dose of Dapagliflozin restores GK enzyme activity, significantly improves the second-phase insulin secretion and β-cell glucose sensitivity in individuals with impaired glucose tolerance (IGT)"; second, completion of the Phase I clinical study of the second-generation glucose kinase activator conducted in the usa, which showed that the exposure level of HM-002-1005 tablets at 184.5 mg is equivalent to 75 mg BID of Dapagliflozin tablets. The company will further optimize the dosage form and conduct multiple ascending dose (MAD) clinical development of the second-generation GKA in china and the usa to achieve better therapeutic effects. Note: The second-generation GKA (HM-002-1005) is a prodrug of Hualing Pharmaceutical's new diabetes drug Dapagliflozin. (Source: Financial Associated Press)